Intervacc AB (publ) (IVACC.ST)
SEK 0.95
(0.96%)
SEK 0.95
(0.96%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -88.16 Million SEK | -94.28% |
| 2022 | -45.37 Million SEK | 60.64% |
| 2021 | -115.27 Million SEK | 29.65% |
| 2020 | -163.86 Million SEK | -216.36% |
| 2019 | -51.79 Million SEK | -46.14% |
| 2018 | -35.44 Million SEK | -173.71% |
| 2017 | -12.94 Million SEK | -222.34% |
| 2016 | 10.58 Million SEK | 86.96% |
| 2015 | 5.66 Million SEK | 539.84% |
| 2014 | -1.28 Million SEK | 64.16% |
| 2013 | -3.59 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -62.52 Million SEK | 12.85% |
| 2024 Q1 | -71.74 Million SEK | 18.62% |
| 2023 Q2 | -113.11 Million SEK | -225.26% |
| 2023 FY | -88.16 Million SEK | -94.28% |
| 2023 Q4 | -88.16 Million SEK | 10.49% |
| 2023 Q1 | -34.77 Million SEK | 23.36% |
| 2023 Q3 | -98.49 Million SEK | 12.92% |
| 2022 Q3 | -64.76 Million SEK | 15.1% |
| 2022 Q1 | -93.78 Million SEK | 18.64% |
| 2022 FY | -45.37 Million SEK | 60.64% |
| 2022 Q2 | -76.28 Million SEK | 18.66% |
| 2022 Q4 | -45.37 Million SEK | 29.94% |
| 2021 FY | -115.27 Million SEK | 29.65% |
| 2021 Q1 | -148.82 Million SEK | 9.18% |
| 2021 Q4 | -115.27 Million SEK | 10.04% |
| 2021 Q3 | -128.14 Million SEK | 9.24% |
| 2021 Q2 | -141.18 Million SEK | 5.13% |
| 2020 Q2 | -179.49 Million SEK | -333.26% |
| 2020 Q1 | -41.42 Million SEK | 20.02% |
| 2020 Q3 | -171.41 Million SEK | 4.5% |
| 2020 FY | -163.86 Million SEK | -216.36% |
| 2020 Q4 | -163.86 Million SEK | 4.4% |
| 2019 FY | -51.79 Million SEK | -46.14% |
| 2019 Q2 | -15.92 Million SEK | 44.0% |
| 2019 Q4 | -51.79 Million SEK | 17.5% |
| 2019 Q3 | -62.78 Million SEK | -294.19% |
| 2019 Q1 | -28.44 Million SEK | 19.76% |
| 2018 Q2 | -46.04 Million SEK | -522.11% |
| 2018 FY | -35.44 Million SEK | -173.71% |
| 2018 Q4 | -35.44 Million SEK | 21.27% |
| 2018 Q3 | -45.01 Million SEK | 2.24% |
| 2018 Q1 | -7.4 Million SEK | 42.84% |
| 2017 Q3 | -28.37 Million SEK | 21.89% |
| 2017 Q4 | -12.94 Million SEK | 54.36% |
| 2017 FY | -12.94 Million SEK | -222.34% |
| 2017 Q1 | -5.1 Million SEK | -148.23% |
| 2017 Q2 | -36.32 Million SEK | -611.62% |
| 2016 Q4 | 10.58 Million SEK | 0.0% |
| 2016 Q1 | 12.59 Million SEK | 0.0% |
| 2016 FY | 10.58 Million SEK | 86.96% |
| 2015 FY | 5.66 Million SEK | 539.84% |
| 2014 FY | -1.28 Million SEK | 64.16% |
| 2013 FY | -3.59 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alzinova AB (publ) | -21.22 Million SEK | -315.34% |
| Amniotics AB (publ) | -5.63 Million SEK | -1465.341% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -3979.593% |
| BioArctic AB (publ) | -606.58 Million SEK | 85.466% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 1732.593% |
| Genovis AB (publ.) | -43.94 Million SEK | -100.633% |
| LIDDS AB (publ) | -13.51 Million SEK | -552.457% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 265.643% |
| OncoZenge AB (publ) | -12.62 Million SEK | -598.186% |
| Saniona AB (publ) | 40.44 Million SEK | 317.964% |
| Simris Alg AB (publ) | 85.07 Million SEK | 203.626% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 73.575% |
| AcouSort AB (publ) | -23.98 Million SEK | -267.548% |
| Active Biotech AB (publ) | -33.2 Million SEK | -165.542% |
| Camurus AB (publ) | -1.16 Billion SEK | 92.435% |
| Cantargia AB (publ) | -139.74 Million SEK | 36.915% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -9451.463% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | -5.277% |
| Mendus AB (publ) | -96.29 Million SEK | 8.447% |
| Kancera AB (publ) | -45.69 Million SEK | -92.944% |
| Karolinska Development AB (publ) | -82.2 Million SEK | -7.248% |
| Lipum AB (publ) | -8.46 Million SEK | -941.465% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | -176.13% |
| NextCell Pharma AB | -46.79 Million SEK | -88.414% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 153.084% |
| Xintela AB (publ) | -7.8 Million SEK | -1028.954% |
| Ziccum AB (publ) | -2.13 Million SEK | -4025.409% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | -200.038% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | -362.539% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 36.184% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 31.92% |
| CombiGene AB (publ) | -101.44 Million SEK | 13.091% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | -7.4% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | -76.246% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | -76.553% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 529.839% |
| Corline Biomedical AB | -17.01 Million SEK | -418.222% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | -5.274% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | -123.859% |
| Aptahem AB (publ) | 2.9 Million SEK | 3130.968% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 73.209% |
| Fluicell AB (publ) | -2.76 Million SEK | -3090.735% |
| Biovica International AB (publ) | -58.73 Million SEK | -50.093% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | -94.971% |
| Abliva AB (publ) | -57.24 Million SEK | -54.018% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 54.72% |
| 2cureX AB (publ) | -13.4 Million SEK | -557.763% |
| I-Tech AB | -83.26 Million SEK | -5.883% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 165.445% |
| Cyxone AB (publ) | -16.67 Million SEK | -428.854% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | -57.75% |
| Biosergen AB | -1.88 Million SEK | -4581.891% |
| Nanologica AB (publ) | -9.38 Million SEK | -839.071% |
| SynAct Pharma AB | -61.75 Million SEK | -42.751% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | -311.674% |
| BioInvent International AB (publ) | -236.3 Million SEK | 62.692% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -566.406% |
| Oncopeptides AB (publ) | -66.92 Million SEK | -31.739% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -1601.628% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | -323.989% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -2866.353% |